Literature DB >> 9648084

Immunologic function and survival in hemodialysis patients.

P L Kimmel1, T M Phillips, S J Simmens, R A Peterson, K L Weihs, S Alleyne, I Cruz, J A Yanovski, J H Veis.   

Abstract

BACKGROUND: Although the medical determinants of mortality in patients with end-stage renal disease (ESRD) treated with hemodialysis (HD) are well appreciated, the contribution of immunologic parameters to survival in such patients is unclear, especially when variations in age, medical comorbidity and nutrition are controlled. In addition, although dysregulation of cytokine metabolism has been appreciated in patients with ESRD, the association of these parameters with outcomes has not been established. Recently, the type of dialyzer used in patients' treatment has been associated with survival, but the mechanisms underlying these findings, including their immune effects, have not been established. We conducted a prospective, cross-sectional, observational multicenter study of urban HD patients to determine the contribution of immunological factors to patient survival. We hypothesized increased proinflammatory cytokines would be associated with increased mortality, and that improved immune function would be associated with survival.
METHODS: Patients were assessed using demographic and anthropometric indices, Kt/V, protein catabolic rate (PCR) and immunologic variables including circulating cytokine [interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-12, IL-13 and tumor necrosis factor (TNF)-alpha] levels, total hemolytic complement activity (CH50), and T cell number and function. A severity index, previously demonstrated to be a mortality marker, was used to grade medical comorbidity. A Cox proportional hazards model, controlling for patients' age, severity index, level of serum albumin concentration, dialyzer type and dialysis site was used to asses relative survival risk.
RESULTS: Two hundred and thirty patients entered the study. The mean (+/- SD) age of the population was 54.4 +/- 14.2 years, mean serum albumin concentration was 3.86 +/- 0.47 g/dl, mean PCR was 1.1 +/- 0.28 g/kg/day, and mean Kt/V 1.2 +/- 0.3. Patients' serum albumin concentration was correlated with levels of Kt/V and PCR, and their circulating IL-13 and TNF-alpha levels, but negatively with their circulating IL-2 levels, T-cell number and T-cell antigen recall function. T-cell antigen recall function correlated negatively with PCR, but not Kt/V. There was no correlation of any other immune parameter and medical or demographic factor. Immune parameters, were all highly intercorrelated. Mean level of circulating cytokines in HD patients were in all cases greater than those of a normal control group. There were few differences in medical risk factors or immune parameters between patients treated with different types of dialyzers. After an almost three-year mean follow-up period, increased IL-1, TNF-alpha, IL-6, and IL-13 levels were significantly associated with increased relative mortality risk, while higher levels of IL-2, IL-4, IL-5, IL-12, T-cell number and function, and CH50 were associated with improved survival. The difference in survival between patients treated with unmodified cellulose dialyzers and modified or synthetic dialyzers approached the level of statistical significance, but there were no differences in levels of circulating cytokines between these two groups.
CONCLUSIONS: Higher levels of circulating proinflammatory cytokines are associated with mortality, while immune parameters reflecting improved T-cell function are associated with survival in ESRD patients treated with HD, independent of other medical risk factors. These factors may serve as markers for outcome. The mechanism underlying the relationship of immune function and survival, and the effect of interventions to normalize immune function in HD patients should be studied.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648084      PMCID: PMC6146918          DOI: 10.1046/j.1523-1755.1998.00981.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

Review 1.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway.

Authors:  W E Mitch; A L Goldberg
Journal:  N Engl J Med       Date:  1996-12-19       Impact factor: 91.245

2.  Lymphocyte transformation in vitro. I. Tissue culture conditions and quantitative measurements.

Authors:  P T Schellekens; V P Eijsvoogel
Journal:  Clin Exp Immunol       Date:  1968-07       Impact factor: 4.330

3.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.

Authors:  W F Owen; N L Lew; Y Liu; E G Lowrie; J M Lazarus
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

4.  T cell subsets and cellular immunity in end-stage renal disease.

Authors:  K Raska; J Raskova; S M Shea; R M Frankel; R H Wood; J Lifter; I Ghobrial; R P Eisinger; L Homer
Journal:  Am J Med       Date:  1983-11       Impact factor: 4.965

5.  Effect of renal replacement therapy on cellular cytokine production in patients with renal disease.

Authors:  P L Kimmel; T M Phillips; E Phillips; J P Bosch
Journal:  Kidney Int       Date:  1990-07       Impact factor: 10.612

6.  Effects of dose of dialysis on morbidity and mortality.

Authors:  R M Hakim; J Breyer; N Ismail; G Schulman
Journal:  Am J Kidney Dis       Date:  1994-05       Impact factor: 8.860

7.  Eosinophilia and cellular cytokine responsiveness in hemodialysis patients.

Authors:  J Hertel; P L Kimmel; T M Phillips; J P Bosch
Journal:  J Am Soc Nephrol       Date:  1992-12       Impact factor: 10.121

8.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

9.  Behavioral compliance with dialysis prescription in hemodialysis patients.

Authors:  P L Kimmel; R A Peterson; K L Weihs; S J Simmens; D H Boyle; D Verme; W O Umana; J H Veis; S Alleyne; I Cruz
Journal:  J Am Soc Nephrol       Date:  1995-04       Impact factor: 10.121

10.  Chemiluminescent enzyme immunoassay of alpha-fetoprotein based on an adamantyl dioxetane phenyl phosphate substrate.

Authors:  G H Thorpe; I Bronstein; L J Kricka; B Edwards; J C Voyta
Journal:  Clin Chem       Date:  1989-12       Impact factor: 8.327

View more
  102 in total

1.  Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis.

Authors:  Jorge L Gamboa; Baback Roshanravan; Theodore Towse; Chad A Keller; Aaron M Falck; Chang Yu; Walter R Frontera; Nancy J Brown; T Alp Ikizler
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-26       Impact factor: 8.237

2.  Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.

Authors:  Wei Ling Lau; Shu-Man Liu; Sogol Pahlevan; Jun Yuan; Mahyar Khazaeli; Zhenmin Ni; Jefferson Y Chan; Nosratola D Vaziri
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

3.  Risk factors for chronic kidney diseases may include periodontal diseases, as estimated by the correlations of plasma pentraxin-3 levels: a case-control study.

Authors:  A R Pradeep; Rahul Kathariya; P Arjun Raju; R Sushma Rani; Anuj Sharma; N M Raghavendra
Journal:  Int Urol Nephrol       Date:  2011-06-03       Impact factor: 2.370

4.  Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1.

Authors:  Asada Leelahavanichkul; Yuning Huang; Xuzhen Hu; Hua Zhou; Takayuki Tsuji; Richard Chen; Jeffrey B Kopp; Jürgen Schnermann; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2011-08-10       Impact factor: 10.612

5.  Fostering Innovation in Symptom Management among Hemodialysis Patients: Paths Forward for Insomnia, Muscle Cramps, and Fatigue.

Authors:  Jennifer E Flythe; Tandrea Hilliard; Elena Lumby; Graciela Castillo; Jazmine Orazi; Emaad M Abdel-Rahman; Amy Barton Pai; Matthew Bertrand Rivara; Wendy L St Peter; Steven Darrow Weisbord; Caroline M Wilkie; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-05       Impact factor: 8.237

6.  Effect of Chronic Uremia on the Cell Surface Expression of B7 Family Costimulatory Molecules in an HLA-A2 Transgenic Mouse Model of Chronic Kidney Disease.

Authors:  Paul E Makidon; Douglas M Smith; Jeffery V Groom Ii; Zhengyi Cao; Jeffery J Landers; James R Baker
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

7.  Effect of chronic dementia caregiving and major transitions in the caregiving situation on kidney function: a longitudinal study.

Authors:  Roland von Känel; Brent T Mausbach; Joel E Dimsdale; Paul J Mills; Thomas L Patterson; Sonia Ancoli-Israel; Michael G Ziegler; Susan K Roepke; Elizabeth A Chattillion; Matthew Allison; Igor Grant
Journal:  Psychosom Med       Date:  2012-01-27       Impact factor: 4.312

Review 8.  Epigenetics of progression of chronic kidney disease: fact or fantasy?

Authors:  Maria R Wing; Ali Ramezani; Harindarpal S Gill; Joseph M Devaney; Dominic S Raj
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

9.  Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.

Authors:  Jason R Stubbs; Arun Idiculla; Joyce Slusser; Rochelle Menard; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2009-12-10       Impact factor: 10.121

Review 10.  Renal cell therapy and beyond.

Authors:  Joon Ho Song; H David Humes
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.